Several studies showed that KRAS mutations in patients with NSCLC have a negative impact on OS, progression-free survival (PFS) and disease control rate (DCR) [8,9]; moreover, patients develop liver and brain metastases more frequently in the presence of this mutation and experience a more aggressive form of the disease [8]. Here, KRAS is linked to non-small cell lung carcinoma.